Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anthroposophic supportive medicine for toxicity reduction in children receiving cancer therapy
ISRCTN64676790Phase 4Completed
- Sponsor
- Helixor Heilmittel GmbH
- Start
- Nov 2005
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of viscum album extract in leukemia, lymphoma and Nonhematologic neoplasms (2 arms), sponsored by Helixor Heilmittel GmbH. Primary endpoint: Treatment-related toxicity. Started Nov 2005; status: completed.
02
Drugs
viscum album extract
03
Conditions
leukemialymphomaNonhematologic neoplasms
Beyond the preview
Go deeper on ISRCTN64676790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN64676790.